SOR-C13 TFA
Based on 1 publication(s) in Google Scholar
SOR-C13 TFA, a carboxy-terminal truncated peptide, is a high-affinity TRPV6 antagonist with an IC50 value of 14 nM. TRPV6 is a non-voltage gated calcium channel that is associated with malignancy and poor prognosis in breast cancer. SOR-C13 TFA has anticancer activity.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.32%
- Formule: C72H116N20O19.xC2HF3O2
- Masse moléculaire:1565.81 (free acid)
-
Stockage:
Sealed storage, away from moisture and light.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) SOR-C13 TFA
More
Activité biologique
|
TRPV6 14 nM (IC50) |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female NOD/SCID mice with SKOV-3 cell[2]
-
Dosage:400, 600, 800 mg/kg
-
Administration:IP; daily; on days 1 to 12
-
Result:Effectively inhibited the growth of tumor.
Chemical Information
-
Appearance Solid
-
Masse moléculaire 1565.81 (free acid)
-
Formule C72H116N20O19.xC2HF3O2
-
Color White to off-white
-
Sequence
Lys-Glu-Phe-Leu-His-Pro-Ser-Lys-Val-Asp-Leu-Pro-Arg
-
Sequence Shortening
KEFLHPSKVDLPR
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Sealed storage, away from moisture and light
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Food Res Int
Disruption of the gut microbiota induces the LCA/TRPV6 signalling axis, impairing desmosome junctions in vitamin A-deficient rats. [Abstract]2025 Dec;222(Pt 1):117656. PMID: 41267264
Solvant et solubilité
H2O : 100 mg/mL (Need ultrasonic)
DMSO : 100 mg/mL (Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Pureté et documentation
-
Fiche technique (272 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. S Fu , et al. Erratum to: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2017 Jun;35(3):397. [Content Brief]
[2]. Hui Xue, et al. Inhibition of Transient Receptor Potential Vanilloid 6 channel, elevated in human ovarian cancers, reduces tumour growth in a xenograft model. J Cancer. 2018 Aug 6;9(17):3196-3207. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
SOR-C13 TFA Related Classifications
HY-P1651A Related Classifications
Powered by Bioz